Unlocking the Promise of Cell Therapy T-Cell Engineering Reimagined A therapeutic pipeline targeting unmet clinical needs in Oncology and Autoimmune disease About Senza5™ Technology Clinical Stage Cell Therapy Company NEXT GENERATION CELL THERAPY TECHNOLOGY Incorporates the latest technological advancements in cell therapy & gene editing by field-leading pioneers. PROPRIETARY SENZA5™ PLATFORM TECHNOLOGY Unprecedented utility and […]
Investors 1
| Date | Name | Website |
| - | BioAdvance | bioadvance... |
Mentions in press and media 3
| Date | Title | Description |
| 20.12.2023 | Philly Money Moves: Biotech firm Vivodyne raised $38M for lab-grown organ development | Money Moves is a column where we chart the raises, mergers and other funding news of tech companies across the region on the third Wednesday of the month. Have a tip? Email us at philly@technical.ly. Update: Mention of PolicyMap's Series A ... |
| 14.11.2023 | Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies | - |
| - | Vittoria Biotherapeutics | “Pioneering the Next Generation of Cell Therapies Reimagining T cell engineering A therapeutic pipeline targeting unmet clinical needs About Senza5™ Technology Cell Therapy “3.0” Company with Clinical Stage Lead Program CELL THERAPY “3.0” T... |